Business context and reporting period
Filing-period note: The request identifies “2021 Q4,” but the supplied filing is Estée Lauder Companies Inc.’s Form 10-K for the fiscal year ended June 30, 2022, filed August 24, 2022. The supplied text does not provide a clear standalone Q4 income statement; this summary covers fiscal 2022 and compares it with fiscal 2021.
The company sells prestige skin care, makeup, fragrance and hair care products in approximately 150 countries and territories through its brand portfolio and retail, travel-retail and online channels.
Financial results and key metrics
| Metric | FY2022 | FY2021 | Change / context |
|---|---|---|---|
| Net sales | $17.737 billion | $16.215 billion | Up 9% reported; up 10% in constant currency |
| Gross profit / margin | $13.432 billion / 75.7% | $12.381 billion / 76.4% | Margin down 0.7 percentage point |
| Operating income / margin | $3.170 billion / 17.9% | $2.618 billion / 16.1% | Income up 21%; adjusted operating income rose 14% |
| Net earnings attributable to Estée Lauder | $2.390 billion | $2.870 billion | Down 17% |
| Diluted EPS | $6.55 | $7.79 | Down 16%; adjusted diluted EPS was $7.24 vs. $6.45, up 12% |
| Operating cash flow | $3.040 billion | $3.631 billion | Down, reflecting working-capital needs and higher taxes |
| Cash and cash equivalents | $3.957 billion | $4.958 billion | Down $1.001 billion |
| Total debt | $5.412 billion | $5.569 billion | Debt / total capitalization rose to 49% from 48% |
FY2022 net earnings included $241 million of goodwill and other intangible and long-lived asset impairments. FY2021 included an $848 million gain from remeasuring the previously held DECIEM investment, a major reason reported net earnings and EPS declined year over year despite higher sales and operating income. The company reported no borrowings on its $2.5 billion revolving credit facility or commercial paper program at June 30, 2022; it said cash, operating cash flows and available credit supported expected needs.
Sales by category: skin care $9.886 billion (+4%), makeup $4.667 billion (+11%), fragrance $2.508 billion (+30%), and hair care $631 million (+11%). Fragrance was the fastest-growing category. By region, The Americas generated $4.623 billion (+22%), Europe, the Middle East & Africa $7.681 billion (+11%), and Asia/Pacific $5.437 billion (-1%).
Material changes versus the prior comparable period
- Sales recovery in physical retail, makeup use occasions and travel retail supported growth, alongside pricing, product launches and DECIEM consolidation. Online sales grew double digits.
- China’s COVID-related restrictions and travel disruption pressured Asia/Pacific sales, including during the second half of FY2022; the region’s sales decreased 1%.
- Gross margin contracted due to manufacturing and logistics costs and business mix, partly offset by favorable transactional foreign exchange and price increases. Higher shipping costs also weighed on expenses.
- Operating cash flow fell as inventory increased by $602 million and working-capital requirements rose. Capital expenditures increased to $1.040 billion from $637 million.
- The company repurchased $2.309 billion of shares and paid $840 million in dividends during FY2022.
Outlook, management commentary, risks and unusual items
- Outlook: The filing does not provide specific FY2023 sales or earnings guidance in the supplied text. Management emphasized long-term investment in innovation, digital and omnichannel capabilities, travel retail and operational efficiency, while noting continued uncertainty.
- Restructuring: The Post-COVID Business Acceleration Program’s estimated total pretax charges increased to $500–$515 million, from the prior $400–$500 million estimate. Expected annual pretax benefits increased to $390–$410 million, with some savings to be reinvested. The program targets a net reduction of 2,500–3,000 positions and closure of approximately 10%–15% of freestanding stores; most approved initiatives are expected to be substantially completed through FY2023.
- Impairments: FY2022 trademark impairment charges totaled $241 million, including $230 million related to Dr.Jart+ and $11 million for GLAMGLOW. Management noted DECIEM’s reporting-unit carrying value approximated fair value, making impairment assumptions and future performance important to monitor.
- Geopolitical exposure: The company suspended commercial activity and business initiatives in Russia and Ukraine in March 2022; these markets represented approximately 1% of FY2022 sales. It liquidated most remaining in-market Russian inventory in July 2022. Further effects remain uncertain.
- Licenses: Agreements for Donna Karan New York, DKNY, Michael Kors, Tommy Hilfiger and Ermenegildo Zegna ended early on June 30, 2022. Those lines accounted for approximately 1% of consolidated sales and 10% of fragrance sales in FY2022.
- Concentration and other risks: The largest customer, primarily serving China travel retail, represented 13% of sales and 24% of accounts receivable at June 30, 2022. Key risks include COVID-related disruption, China and travel-retail exposure, inflation, supply-chain constraints, foreign exchange, competition, cybersecurity and customer credit risk. The Lauder family held approximately 84% of voting power, creating significant control and influence.
- Management said current litigation and reasonably possible additional losses were not expected to have a material adverse effect; the filing describes legal matters including product liability and asbestos-related claims.
Important facts for investors to verify
- Confirm the intended period: the supplied filing is FY2022, not a 2021 Q4 filing; obtain quarterly disclosures for standalone Q4 results.
- Assess underlying earnings using the company’s non-GAAP reconciliations, particularly the FY2021 DECIEM remeasurement gain and FY2022 impairments and restructuring charges.
- Track China restrictions, travel-retail recovery and the largest customer’s sales and receivable concentration.
- Monitor gross-margin recovery, inventory and operating cash flow as supply-chain costs and working-capital needs evolve.
- Verify delivery of PCBA savings, store and workforce reductions, and remaining charges against management’s revised estimates.
- Review DECIEM and Dr.Jart+ performance and impairment assumptions, including sensitivity to forecasts and discount rates.